In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on AC Immune SA (ACIU), with a price target of $18. The company’s shares opened today at $10.35.
Fein wrote:
“We hosted a management breakfast (January 9, 2019) in the JPM (JPM; not rated) healthcare conference with AC Immune’s CEO, Andrea Pfeifer. During the discussions with management, a key focus from investors was on the interim analysis of crenezumab’s CREAD1 Phase 3 trial this year, and the role of effector function in targeting mis-folded proteins in the brain. We have limited clarity on the timing or the type of crenezumab’s interim analysis based on the conversations with management, and believe that this event remains a critical inflection point for the company. We think that the updated BAN2401 and aducanumab data collectively lend support to amyloid hypothesis and should have positive read-through to crenezumab.”
According to TipRanks.com, Fein is a 4-star analyst with an average return of 6.6% and a 44.5% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for AC Immune SA with a $17.33 average price target.
See today’s analyst top recommended stocks >>
Based on AC Immune SA’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $13.74 million. In comparison, last year the company had a net profit of $4.22 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AC Immune SA is a clinical stage biopharmaceutical company, which engages in developing therapeutic and diagnostic products. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding.
